| Literature DB >> 34199738 |
Laura Hoen1, Daniel Pfeffer1,2, Rico Zapf1,2, Andrea Raabe3, Janosch Hildebrand1, Johannes Kraft2, Stefan Kalkhof1,4.
Abstract
Due to multifactorial reasons, such as decreased thirst and decreased total body water, elderly patients are vulnerable to dehydration. Mild cognitive impairment (MCI) or dementia increase the risk of dehydration and, in turn, dehydration decreases cognitive performance. The study aims to identify and assess differences in hydration status, taking into account patients' drug treatment and diseases, using bioelectrical impedance vector analysis (BIVA), thereby revealing unfavorable aspects of prognosis. 447 geriatric patients (241 women, 206 men) including information on medication and bioelectrical impedance analysis (BIA) were investigated, which allowed studying the association between 40 drugs and the hydration status. First, patients were divided into disease groups. Renal disease and diuretic treatment were significantly different in both sexes, whereas cardiovascular patients differed exclusively for females. Next, drug enrichment was examined in either hyperhydrated or dehydrated patients. Simvastatin, candesartan, bisoprolol, amlodipine, olmesartan, furosemide, torasemide, allopurinol, mirtazapine, pantoprazole, cholecalciferol, and resveratrol showed enrichment depending on hydration status. This study demonstrated that patients can be differentiated and stratified by BIVA, taking into account medication and disease associated with hydration status. Although patients diagnosed with MCI and therefore treated with resveratrol, BIVA still showed evaluated dehydration. This is unfavorable in terms of prognosis and requires special attention.Entities:
Keywords: body composition; clinical nutrition; drug-nutrient interactions; geriatrics; malnutrition; nutrition; nutrition assessment; prevention
Year: 2021 PMID: 34199738 PMCID: PMC8226953 DOI: 10.3390/nu13061929
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1Subdivision Model of Z-Scores based on 50%, 75% and 95% tolerance ellipses A: Annotation of the 50%, 75% and 95% tolerance ellipses based on Norman et al. [21]. Sectors M and I (dehydrated), K and O (hydrated), and A, B, C, D (control) were defined to classify the patients according to the hydration status.
Figure 2(a–d): Distribution of the Coburg patients in a Bioelectrical Impedance Vector Analyses (male (a,c), female (b,d)) plotted against reported tolerance intervals of the reference population reported by Roubenoff et al. (a + b) and against tolerance ellipses calculated based on all 447 patients being included in the Coburg’s cohort (c + d).
Figure 3Confidence Ellipses in the RXc graphs for the different subgroups and each gender: renal (a), diuretic (b), cardiovascular (c) and dementia (d), * = p < 0.01, ** = p < 0.005, *** = p < 0.005.
Baseline Characteristics and impedance values of the patients classified by hydration status (see also Figure 1), average ± standard deviation, * = p ≤ 0.05, ** = p ≤ 0.005, *** = p ≤ 0.0001.
| Characteristics | Dehydrated | Normal-Hydrated | Hyperhydrated |
|---|---|---|---|
| N | 46 | 225 | 27 |
| Male/Female | 18/28 | 109/116 | 13/14 |
| Height [cm] | 165.4 ± 9.5 | 167.7 ± 9.3 | 173.6 ± 8.9 ** |
| Age [yr] | 78.3 ± 8.5 * | 80.6 ± 6.4 | 77.9 ± 6.6 * |
| Weight [kg] | 66.1 ± 12.8 ** | 73.1 ± 11.8 | 86.1 ± 15.7 *** |
| BMI [kg/m2] | 24.1 ± 3.6 ** | 26.0 ± 3.4 | 28.6 ± 4.8 ** |
| Sodium [mmol/L] | 141.7 ± 2.6 | 141.0 ± 2.9 | 141.6 ± 2.8 |
| Hematocrit [L/L] | 0.417 ± 0.036 ** | 0.398 ± 0.038 | 0.382 ± 0.050 * |
| Urea [mmol/L] | 9.1 ± 8.2 | 7.7 ± 3.5 | 7.6 ± 0.9 |
| Creatinine [µmol/L] | 82.5 ± 28.8 ** | 99.2 ± 33.9 | 114.9 ± 42.1 * |
| Glucose [mmol/L] | 5.9 ± 1.4 * | 6.6 ± 2.2 | 6.3 ± 1.4 |
| Total Number of Medication | 5.2 ± 3.6 ** | 7.6 ± 4.3 | 9.3 ± 4.0 |
| PhA [°] | 4.5 ± 0.7 ** | 4.1 ± 0.4 | 3.8 ± 0.8 ** |
| Z [Ohm] | 647.8 ± 64.1 *** | 543.1 ± 57.5 | 458.1 ± 57.4 *** |
| Xc [Ohm] | 49.8 ± 5.2 *** | 39.1 ± 4.7 | 29.9 ± 5.8 *** |
| R [Ohm] | 645.8 ± 64.4 *** | 541.7 ± 57.4 | 457.0 ± 57.5 *** |
| R/H [Ohm/m] | 392.3 ± 48.9 *** | 324.6 ± 43.4 | 264.5 ± 39.5 *** |
| Xc/H [Ohm/m] | 30.2 ± 3.4 *** | 23.4 ± 3.1 | 17.3 ± 3.6 *** |
Enriched medication in the dehydrated and hyperhydrated group.
| Class | Compound | T | log2(FC) | |||||
|---|---|---|---|---|---|---|---|---|
| Hyperhydrated | Dehydrated |
|
| |||||
| Hotelling | B&H | Hotelling | B&H | |||||
| 1 | Simvastatin | 43 |
| −2.70 |
|
| 0.6472 | 0.6766 |
| Metoprolol | 17 |
| - | 0.2066 | 0.2794 |
| 0.0553 | |
| Candesartan | 84 |
| −0.81 |
|
| 0.6766 | 0.6766 | |
| Apixaban | 33 |
| −1.45 |
| 0.0805 | 0.1692 | 0.2417 | |
| Bisoprolol | 131 |
| −0.70 |
|
| 0.4214 | 0.4862 | |
| Amlodipine | 61 |
| −0.62 | 0.1580 | 0.2370 |
|
| |
| Amlodipine/Olmesartan | 17 | - |
| 0.2315 | 0.2894 |
|
| |
| Olmesartan | 19 | - |
| 0.6579 | 0.6766 |
|
| |
| 2 | Furosemide | 19 |
| - |
|
| 0.0840 | 0.1400 |
| Torasemide | 93 |
| * −1.69 |
|
| 0.2142 | 0.2794 | |
| 3 | Allopurinol | 46 |
| −0.92 |
|
| 0.3690 | 0.4428 |
| 4/7 | Resveratrol | 45 | −1.87 |
|
|
|
|
|
| 5 | Mirtazapine | 35 | −0.97 |
|
|
| 0.1305 | 0.2061 |
| 6 | Pantoprazole | 85 |
| −1.32 |
|
| 0.5671 | 0.6301 |
| 7 | Cholecalciferol | 220 |
| −0.62 |
|
|
|
|
Class shows the classification of the compound (1 = Cardiac, 2 = Diuretic, 3 = Endocrinology, 4 = Dementia/Mild Cognitive Impairment, 5 = psychotic/neurological, 6 = gastrointestinal, 7 = nutritional supplements), T = total amount, log2(FC) = binary logarithm, Fisher’s exact test: * = p < 0.05, ** = p < 0.005; Hotelling’s T test: p♀/p♂ with and without adjustment for multiple testing using Benjamini & Hochberg’s method, gender-specific p-values (referring to extreme group vs. normal hydrated group) and log2(FC) are highlighted in bold if being significant (p < 0.05).
Figure 4Confidence Ellipses in the RXc graph for resveratrol: (A—female, B—male) Significant differentiation of male (p = 0.0158) and female (p = 0.0124) patients receiving resveratrol.